Offers worth pausing over
Pause when the offer avoids a direct answer
Before spending money, try asking a short question. A long answer that leaves out the product or pharmacy name is a reason to keep asking.
Prescription, source and follow-up
The September 2026 federal record requires a valid prescription before a prescription drug is dispensed.
The FDA warns about services where no doctor or other health professional is available to answer questions after the medicine arrives.
The word compounded describes a medicine made by mixing or changing ingredients for a patient, usually by a pharmacist or doctor.
Calling a compounded preparation FDA-approved is false under the September 2026 position.
A label cannot answer every question
Letters included in the September 2026 check show the FDA challenging sellers that offered human treatments while putting research wording on their labels. Examples include “for research use only” and the separate wording “not for human consumption”. Those were seller labels, rather than an invitation to join a medical study.
Those letters are allegations against particular firms, not court judgments.
Some labels for compounded weight medicines named pharmacies that did not exist, according to the FDA’s September 2026 record.
Ask who will treat you and which pharmacy will send the medicine; get both full names. Look up each in the right state licensing board’s records. If the names do not match, ask the service to explain before deciding whether to proceed.
Keep price in its proper place
The FDA flags implausibly deep discounts, but price alone cannot separate a legitimate offer from a suspect one.
Ask what is included and what happens after the introductory period. Keep a low price from replacing the questions about care.